HC Wainwright Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00

Key Points

• HC Wainwright has lowered the price target for Day One Biopharmaceuticals from $36.00 to $25.00, maintaining a "buy" rating for the stock.
• The company's stock is currently trading at around $6.88, significantly below the new target price, indicating a potential upside of 263.37%.
• In the latest earnings report, Day One Biopharmaceuticals posted an EPS of ($0.29), outperforming analysts' expectations of ($0.35).

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) had its price objective reduced by equities research analysts at HC Wainwright from $36.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 315.56% from the company's current price. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q3 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.51 EPS and FY2029 earnings at $1.01 EPS.

DAWN has been the topic of a number of other reports. Wedbush reaffirmed an "outperform" rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has an average rating of "Buy" and an average price target of $25.33.

Day One Biopharmaceuticals Stock Down 0.2%

Day One Biopharmaceuticals stock traded down $0.01 during trading hours on Wednesday, hitting $6.02. The stock had a trading volume of 306,474 shares, compared to its average volume of 1,354,083. The stock's 50-day moving average price is $6.70 and its 200-day moving average price is $8.09. The stock has a market capitalization of $609.79 million, a P/E ratio of -6.34 and a beta of -1.26. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. The company had revenue of $33.91 million during the quarter, compared to analyst estimates of $35.55 million. On average, research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Adam Dubow sold 4,552 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $28,495.52. Following the completion of the sale, the general counsel owned 47,136 shares of the company's stock, valued at $295,071.36. This represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Charles N. York II sold 4,282 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the transaction, the chief financial officer owned 265,231 shares in the company, valued at $1,660,346.06. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,725 shares of company stock valued at $167,299. Insiders own 6.20% of the company's stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC purchased a new stake in Day One Biopharmaceuticals in the first quarter worth about $88,000. Rhumbline Advisers increased its holdings in Day One Biopharmaceuticals by 8.3% in the 1st quarter. Rhumbline Advisers now owns 81,844 shares of the company's stock worth $649,000 after acquiring an additional 6,291 shares in the last quarter. MetLife Investment Management LLC raised its stake in Day One Biopharmaceuticals by 12.4% during the 4th quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock worth $434,000 after acquiring an additional 3,781 shares during the period. Millennium Management LLC raised its stake in Day One Biopharmaceuticals by 80.4% during the 4th quarter. Millennium Management LLC now owns 192,100 shares of the company's stock worth $2,434,000 after acquiring an additional 85,606 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in Day One Biopharmaceuticals by 23.5% during the fourth quarter. ProShare Advisors LLC now owns 19,394 shares of the company's stock valued at $246,000 after purchasing an additional 3,687 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.